Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers

Background/Objective(s): Few studies have evaluated the therapeutic response among switchers of biologics in patients with psoriasis. We report our experience of ustekinumab in patients with psoriasis who did not respond adequately to tumor necrosis factor (TNF) blockers treatment previously. Method...

Full description

Bibliographic Details

Published in:	Dermatologica Sinica
Main Authors:	Tzu-Chang Wang, Hsien-Yi Chiu, Ting-Shun Wang, Tsen-Fang Tsai
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-03-01
Subjects:	adalimumab biologics switch etanercept PASI (Psoriasis Area and Severity Index) psoriasis ustekinumb
Online Access:	http://www.sciencedirect.com/science/article/pii/S1027811714000536